Pyridostigmine Bromide Tablets
Closed Pre-Solicitation Posted
- Solicitation number
- SPE2DP25R0003
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency - Troop Support is seeking sources to provide Pyridostigmine Bromide Tablets (PB Tabs), a pharmaceutical product with specific FDA requirements. The procurement involves USP 30 MG tablets that are individually sealed, with each package containing 210 tablets and a desiccant. The agency is conducting a Request for Information (RFI) to gather market intelligence about current manufacturers and potential suppliers of this medical product. The RFI invites manufacturers and developers to submit detailed information about their product, including place of manufacture, FDA registration, current unit sales price, inventory levels, delivery capabilities, and product origin. Responses must be submitted electronically in PDF format to Contracting Specialist Rosbert.Jones@dla.mil by May 5, 2025, with the understanding that all submitted information will be kept confidential under federal law.
The contract has no specific set-aside designation and represents an annual estimated requirement of 27,000 packages with a base year and four potential one-year option periods. The tablets will be delivered to the Defense Distribution Center in Norfolk, VA, and must have an FDA-approved shelf life of no less than 120 months. While the RFI does not commit the government to issue a solicitation or make an award, it is part of DLA Troop Support's strategy to develop an appropriate procurement approach for Pyridostigmine Bromide Tablets. The pharmaceutical falls under NAICS category 325412 for Pharmaceutical Preparation Manufacturing and PSC category 6505 for Drugs and Biologicals. Potential suppliers are encouraged to provide comprehensive information about their current manufacturing capabilities, product development stages, and any independent or FDA testing that has been conducted.
Notice text
The Defense Logistics Agency - Troop Support is seeking sources capable of providing Pyridostigmine Bromide Tablets (PB Tabs). Pyridostigmine Bromide Tablets (PB Tablets), USP, 30 MG, Individually Sealed, 210s. NSN 6505-01-178-7903. Tablets shall be in accordance with the specification and requirements of the U.S. Food and Drug Administration and have an FDA approved shelf life of no less than 120 months. The unit of issue for the product is packages. One package shall contain 10 immediate containers in protective sleeves, each containing 21 individually sealed tablets (210 tablets), together with a desiccant, as specified, constitutes one unit.
DLA Troop Support has an annual estimated requirement for Pyridostigmine Bromide Tablets of 27,000 PG’s with a one (1) base year with four (4) one year option periods . However, the quantities may increase or decrease as the Services requirements change. PB Tabs shall be delivered to the Defense Distribution Center (DDC) in Norfolk, VA.
This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make award, or pay any cost associated with responding to the RFI. All submitted information shall remain with the U.S. Government and will not be returned.
*** Currently Marked Pyridostigmine Bromide Tablets ***
If your firm currently markets Pyridostigmine Bromide Tablets, please provide information with respect to the following:
- Place of Manufacture
- Estimated Annual Capacity
- FDA Registration information
- Product Name and description including description of any special features
- Current unit sales price
- Estimated inventory level and storage requirements
- Delivery days for this item and earliest product available time
- Country of origin for API
- Do you have any authorized distributor for this item in the U.S.? If so, please provide the name of the authorized distributor(s).
***New Product Under Development***
For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture products described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.
Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Pyridostigmine Bromide Tablets. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.
Your response to this RFI may be submitted electronically in PDF format and emailed to Contracting Specialist Rosbert.Jones@dla.mil.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Methylphenidate ER | Medical Supply Chain | No set-aside | |
| 6505--Imatinib Tablets | National Acquisition Center | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity